Product & Portfolio Strategy
Iraq
Shape the future of cardiometabolic care by bridging cutting-edge science with the healthcare professionals and digital opinion leaders who influence treatment decisions for millions of pa-tients worldwide
As a Regional Medical Advisor within our Cardiometabolic team, you will be at the intersection of science, strategy, and stakeholder engagement, driving medical education, building trusted relationships with Key Opinion Leaders (KOLs) and Digital Opinion Leaders (DOLs), and translating real-time insights into actions that help shape cardiometabolic care across Iraq.
In Product & Portfolio Strategy we drive commercial strategy, medical affairs and business devel-opment across our therapy areas. We act as a connector and compass, guiding the new Novo Nordisk portfolio for sustained competitiveness upstream, and maximising portfolio potential through successful commercial strategies and competitive launches downstream.
Within this area, the Cardiometabolic Medical Affairs team plays a pivotal role in shaping how Novo Nordisk's diabetes and obesity portfolio is positioned within the broader Cardio-Metabolic-Renal approach. You will join a team of medical professionals who combine scientific rigour with strategic thinking, working closely with commercial, access, and other internal stakeholders to ensure that the best available evidence reaches the HCPs and decision-makers who need it most.
We are looking for a scientifically credible medical advisor who thrives in digital-first engagement and can turn complex data into compelling narratives. You will bring:
At Novo Nordisk, we have spent over a century defeating serious chronic diseases — and today we are reaching more patients than ever before. This dedication has built a company where sci-entific ambition meets genuine care for the people we serve and the colleagues we work along-side. Here, diverse perspectives, shared purpose, and mutual accountability come together to create extraordinary results. When you join us, you step into a high-performance culture where your expertise shapes real outcomes for patients, and where your growth as a professional and as a person truly matters.
Beyond a purpose you can feel in your everyday work, being part of a global healthcare company means access to career development opportunities across functions and geographies, alongside benefits designed to support you at every stage of your career and life.
18 September 2026. Applications are reviewed on an ongoing basis, so we encourage you to ap-ply as soon as possible.

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html